Vitekta

Active Ingredient(s): Elvitegravir
FDA Approved: * September 24, 2014
Pharm Company: * GILEAD SCIENCES INC
Category: HIV / AIDS

Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed[1] by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008.[2][3][4] The drug gained approval by the U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.[5] ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vitekta 85 mg Oral Tablet, Film Coated
NDC: 61958-1301
Labeler:
Gilead Sciences, Inc.
Vitekta 150 mg Oral Tablet, Film Coated
NDC: 61958-1302
Labeler:
Gilead Sciences, Inc.